Napo Signs Commercialization Alliance With AsiaPharm

Napo Pharmaceuticals announced that it has granted AsiaPharm Group an exclusive license to develop and commercialize for China (including Hong Kong and Macau) products derived from crofelemer to treat chronic diarrhea in people living with HIV/AIDS (AIDS-related diarrhea), acute infectious diarrhea and pediatric diarrhea. Crofelemer targets several gastrointestinal indications and is in advanced clinical development to treat AIDS-related diarrhea and diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in the U.S.

PharmaLive (http://www.medadnews.com/News/Index.cfm?articleid=248896)